Model-based comparison of organ at risk protection between VMAT and robustly optimised IMPT plans.

Journal

Zeitschrift fur medizinische Physik
ISSN: 1876-4436
Titre abrégé: Z Med Phys
Pays: Germany
ID NLM: 100886455

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 20 02 2020
revised: 07 09 2020
accepted: 18 09 2020
pubmed: 29 12 2020
medline: 9 10 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

The comparison between intensity-modulated proton therapy (IMPT) and volume-modulated arc therapy (VMAT) plans, based on models of normal tissue complication probabilities (NTCP), can support the choice of radiation modality. IMPT irradiation plans for 50 patients with head and neck tumours originally treated with photon therapy have been robustly optimised against density and setup uncertainties. The dose distribution has been calculated with a Monte Carlo (MC) algorithm. The comparison of the plans was based on dose-volume parameters in organs at risk (OARs) and NTCP-calculations for xerostomia, sticky saliva, dysphagia and tube feeding using Langendijk's model-based approach. While the dose distribution in the target volumes is similar, the IMPT plans show better protection of OARs. Therefore, it is not the high dose confirmation that constitutes the advantage of protons, but it is the reduction of the mid-to-low dose levels compared to photons. This work investigates to what extent the advantages of proton radiation are beneficial for the patient's post-therapeutic quality of life (QoL). As a result, approximately one third of the patients examined benefit significantly from proton therapy with regard to possible late side effects. Clinical data is needed to confirm the model-based calculations.

Identifiants

pubmed: 33358063
pii: S0939-3889(20)30098-2
doi: 10.1016/j.zemedi.2020.09.003
pii:
doi:

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

5-15

Informations de copyright

Copyright © 2020. Published by Elsevier GmbH.

Auteurs

Carina Behrends (C)

West German Proton Therapy Centre Essen (WPE), Essen, Germany; Heinrich-Heine-University, Düsseldorf, Germany; West German Cancer Centre (WTZ), Essen, Germany. Electronic address: carina.behrends@uk-essen.de.

Jan Haussmann (J)

Department of Radiation Oncology, Heinrich-Heine-University, Düsseldorf, Germany.

P-H Kramer (PH)

West German Proton Therapy Centre Essen (WPE), Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany.

Johannes A Langendijk (JA)

Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

Holger Gottschlag (H)

Department of Radiation Oncology, Heinrich-Heine-University, Düsseldorf, Germany.

Dirk Geismar (D)

West German Proton Therapy Centre Essen (WPE), Essen, Germany; Department of Particle Therapy, University Hospital Essen, Essen, Germany.

Wilfried Budach (W)

Department of Radiation Oncology, Heinrich-Heine-University, Düsseldorf, Germany.

Beate Timmermann (B)

West German Proton Therapy Centre Essen (WPE), Essen, Germany; West German Cancer Centre (WTZ), Essen, Germany; Department of Particle Therapy, University Hospital Essen, Essen, Germany; German Cancer Consortium (DKTK), Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH